Telix Pharmaceuticals stock

TLX · ASX · AUD

Compare Telix Pharmaceuticals
$13.25Change from previous close: −0.60%Absolute change: −$0.08

Close · November 18, 2026

Price history

−5.76% over the period

1 year: from $14.06 (November 18, 2025) to $13.25 (November 18, 2026), −5.76%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 18, 2026$13.25
October 30, 2026$13.13
September 30, 2026$15.72
August 31, 2026$15.36
July 31, 2026$14.21
June 30, 2026$16.58
May 29, 2026$13.03
April 30, 2026$15.00
March 31, 2026$13.66
February 27, 2026$10.00
January 30, 2026$10.55
December 31, 2025$11.20
November 28, 2025$15.22
November 18, 2025$14.06

At a glance

  • The company

    Develops therapeutic and diagnostic radiopharmaceuticals for cancer treatment and diagnosis, with lead candidates in prostate cancer, kidney cancer, and glioblastoma

  • Latest results

    Quarter to September 30, 2025 · EPS -$0.14 (estimate $0.08)

TickerLandia's take on Telix Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$8.26
52-wk high$18.22

−27.28% from the 52-week high

Analysts · 12 analysts

Average target$24.17+82.42% vs. price

Buy 11 · Hold 1 · Sell 0 · Buy

TickerLandia Fingerprint: Telix Pharmaceuticals

Compared with similar companies: very low financial strength.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Telix Pharmaceuticals is pricier than similar companies

Telix Pharmaceuticals's P/E (trailing 12 months): 88.9, +27% against the median of a group of 6 similar companies (69.8).

Compared with 6 similar companies

Telix Pharmaceuticals's metrics compared with similar companies
MetricTelix PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)88.9Middle
Operating margin6.2%Middle
ROE7.4%Middle
Debt/equity1.19High
Price/book6.53Middle

Grey band: the middle half of the group; tick: the median; dot: Telix Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$477.35M

Latest quarter · Q2 2026

Net income

$38.33M

Latest quarter · Q2 2026

Quarterly net margin

8.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$4.52B
P/E
88.9
EPS
$0.15
Volume
1.43M
Daily trading
€19.26M
Dividend yield
0.00%

How Telix Pharmaceuticals is changing

All results
  • Revenue grew 188.7% a year on average over the last 5 years

  • Operating margin rose from −46.3% to 2.4%

  • Less cash than profit: free cash flow equal to -54% of net income

Returns

Telix Pharmaceuticals returns

$1,000 invested in Telix Pharmaceuticals 5 years ago, on November 18, 2021, would be worth $1,898 today: +89.83% in total, +13.68% per year. This is the price return only: dividends are excluded.

PeriodTelix PharmaceuticalsS&P/ASX 200$1,000 becomes
1 month−13.96%+0.42%$860
6 months−7.08%+4.44%$929
Year to date+18.30%+1.94%$1,183
1 year−5.76%+4.89%$942
3 years+45.13%+25.85%$1,451
5 years+89.83%+20.38%$1,898

Over the last 6 months it has done better than 12% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Telix Pharmaceuticals: technical analysis

Telix Pharmaceuticals shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 57.5% below its all-time closing high ($31.14, February 25, 2025).

Trend
No clear trend
RSI (14 sessions)
40
Between 30 and 70
vs 200-session average
−6.82%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

Support and resistance

Price areas where Telix Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$15.45+16.60%2 touches, last on September 11, 2026
  2. Resistance$14.94+12.78%3 touches, last on October 2, 2026
  3. Resistance$14.00+5.64%3 touches, last on August 3, 2026
  4. Last price$13.25
  5. Support$12.08−8.83%2 touches, last on June 3, 2026
  6. Support$10.89−17.83%2 touches, last on February 23, 2026

Volatility and risk

Over the last year it has moved less than the S&P/ASX 200.

Beta (1 year) vs S&P/ASX 200
0.80
Volatility (60 sessions, annualised)
55.4%
Largest fall in the last year
−43.59%

In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Telix Pharmaceuticals: seasonality

Average monthly price change over 9 years

+1.4%Jan−5.2%Feb+3.2%Mar+13.9%Apr+7.9%May+6.6%Jun+4.6%Jul+4.2%Aug−0.9%Sep+2.9%Oct+17.5%Nov−2.4%Dec

Over the last 9 years, the strongest month for Telix Pharmaceuticals has been November: +17.50% on average, positive in 6 years out of 8. The weakest has been February: −5.20% on average, positive in 1 years out of 9.

Show chart data
MonthAverageMedianPositive years
January+1.42%−2.48%4 of 9
February−5.20%−3.00%1 of 9
March+3.17%+3.62%5 of 9
April+13.89%+9.81%8 of 9
May+7.90%+9.52%6 of 9
June+6.64%−2.79%4 of 9
July+4.58%+0.62%5 of 9
August+4.21%−2.04%4 of 9
September−0.93%+0.61%5 of 9
October+2.90%+0.96%6 of 9
November+17.50%+7.83%6 of 8
December−2.40%−1.22%2 of 9

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Telix Pharmaceuticals and its competitors

Telix Pharmaceuticals develops and commercializes radiopharmaceuticals, both therapeutic and diagnostic, and its largest segment is Precision Medicine, built around imaging agents such as Illuccix and Gozellix for prostate cancer. Its pipeline includes the lutetium-labeled radio antibody-drug conjugate TLX591, which is in a Phase 3 trial for advanced prostate cancer, along with candidates for kidney cancer, glioblastoma, soft tissue sarcoma and bone metastases.

Headquarters
North Melbourne, Australia
Employees
1,120
Founded
2015
Chief executive
Christian Behrenbruch
Telix Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Telix PharmaceuticalsTLX$3.04B6.2%88.9−7.08%
InSilico Medicine Cayman TopCo3696$2.8B26.6%—−36.01%
3SBio1530$4.56B60.3%3.90−31.48%
Neuren PharmaceuticalsNEU$1.96B19.9%153.2+80.28%
Metis TechBio7666$1.7B-89.6%—−70.16%
MesoblastMSB$1.65B-42.6%—−12.75%

Same industry or related industries, similar size. Compare Telix Pharmaceuticals with its competitors · Full profile